According to a recent report published by Grand View Research Inc., product approval initiatives are likely to accelerate immunoprotein diagnostic testing market expansion.
According to a report, “Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis By Type (Complement System Proteins, Free Light Chain, Haptoglobin, Immunoglobulin), By Technology, By Application, And Segment Forecasts, 2018 – 2025”, published by Grand View Research, Inc. The global immunoprotein diagnostic testing market size is expected to reach USD 10.3 billion by 2025, registering a staggering CAGR, as per a new report by Grand View Research Inc. The market demand can be attributed to the rising incidence of chronic diseases.

According to a 2017 research report by the American Heart Association, nearly 790,000 people suffer heart attack every year in the U.S. Furthermore, stroke is responsible for 1 in every 20 deaths in the country. Hence, WHO is undertaking initiatives to decrease the risk and occurrence of cardiovascular diseases. Such factors are driving the demand for immunoprotein diagnostics and are expected to rise during the forecast period in order to facilitate rapid diagnosis.
According to WHO, nearly 1.69 million deaths were registered due to lung cancer in 2015, worldwide. As a result, fast and accurate diagnosis of chronic diseases has become crucial to reduce the growing mortality rate. Immunoprotein diagnostic devices and reagents have proven to be highly effective in detecting chronic diseases.
Technological advancements in immunoprotein diagnostics have led to the introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.
Click the link below:
https://www.grandviewresearch.com/industry-analysis/immunoprotein-diagnostic-testing-industry
Immunoprotein Diagnostic Testing Market Highlights
- Immunoglobulin tests held the test type segment in 2016 due to its widespread adoption by healthcare professionals to monitor the functioning of a patient’s immune system in autoimmune or infectious diseases.
- C-Reactive Protein (CRP) tests are gaining huge traction as they can assist in monitoring the treatment effectiveness for infectious diseases and cancer. CPR tests also accounted for a significant market share in 2016.
- On the basis of application, infectious disease testing led the market in 2016, followed by oncology testing. Infectious disease testing segment growth can be ascribed to the rising prevalence of chronic infectious diseases, such as HIV/AIDS. Enzyme-based immunoassays are gaining popularity as they are considered rapid testing techniques for disease identification.
- Enzyme-based Immunoassay (EIA) led the market, accounting for the largest revenue share in 2016. Human Complement C3 ELISA Kit developed by Abcam uses EIA technology for diagnosis.








